<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04342624</url>
  </required_header>
  <id_info>
    <org_study_id>19-002074</org_study_id>
    <nct_id>NCT04342624</nct_id>
  </id_info>
  <brief_title>Investigation of Cinnamon Spice on Glucose Tolerance in Subjects With Pre-diabetes</brief_title>
  <acronym>CINNII</acronym>
  <official_title>Effects of Cinnamon Spice on Glucose, Insulin, GI Hormone and Microbiome in Obese Individuals With Pre-Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, Los Angeles</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, Los Angeles</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to determine whether the effectiveness of cinnamon spice capsules vs. placebo&#xD;
      capsules on glucose tolerance in prediabetic subjects who are overweight or obese.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Participants will be asked to take cinnamon spice or placebo capsules daily with breakfast&#xD;
      and dinner (2 weeks of cinnamon, 2 weeks of placebo). The placebo capsule is a study product&#xD;
      that looks like the cinnamon capsules, but contains no active ingredients. The amount of&#xD;
      cinnamon will be 4 grams per day. 2 grams will be taken at breakfast and dinner. Timed blood&#xD;
      collections over a three-hour period will be used to measure how cinnamon spice affects&#xD;
      glucose metabolism/insulin sensitivity in human subjects. Everyone who participates in the&#xD;
      study will receive each treatment in random order. In this way, everyone will receive&#xD;
      cinnamon spice capsules and placebo.&#xD;
&#xD;
      In a crossover study design subjects will consume either cinnamon or placebo with foods and&#xD;
      before bed for 28 days. The placebo capsule is a study product that looks like the cinnamon&#xD;
      capsules, but contains no active ingredients. The participants will also be asked to undergo&#xD;
      an oral glucose tolerance test 4 times (on separate days) before and after the first and&#xD;
      second cinnamon/placebo consumption. Subjects will take 3 capsules of cinnamon or placebo&#xD;
      (total 2 g) with the glucose drink (75 g). Timed blood collections over a three-hour period&#xD;
      will be used to measure how cinnamon spice affects glucose metabolism/insulin sensitivity in&#xD;
      human subject. Continuous glucose monitoring will performed through the entire study for each&#xD;
      subject. The microbiome will also be examined at the beginning and end of each 28 day phase&#xD;
      (0-4 weeks and 6-10weeks). Subjects will consume a brown-beige diet during the study to&#xD;
      exclude the effects of other polyphenol-rich foods. We will enroll twenty subjects &gt;= 20&#xD;
      years of age, overweight/obese (BMI 25 to 35 kg/ m2) with fasting blood sugar between 100 and&#xD;
      126 mg/dl or HbA1c &gt;=5.7% and &lt;= 6.5%.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 14, 2021</start_date>
  <completion_date type="Anticipated">January 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Blood glucose control using glucose tolerance test</measure>
    <time_frame>3 hours</time_frame>
    <description>To determine the effect of cinnamon on glucose tolerance acutely after 75g glucose intake in pre-diabetic overweight/obese individuals</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Blood glucose control with continuous glucose monitoring.</measure>
    <time_frame>4 weeks</time_frame>
    <description>To determine the effect of cinnamon on glucose tolerance for 4 weeks in pre-diabetic overweight/obese individuals</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mircobiome effects of cinnamon through stool sample collection</measure>
    <time_frame>4 weeks</time_frame>
    <description>To determine the effects of cinnamon on gut microbiota, short chain fatty acids, gut hormones GLP-1, GIP,glucagon and metabolomics.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>PreDiabetes</condition>
  <condition>Blood Glucose, High</condition>
  <arm_group>
    <arm_group_label>Cinnamon</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Consume 4g of cinnamon capsules daily. Will be randomized, double blind, cross-over to other arm after.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Consume 4g of placebo daily. Will be randomized, double blind, cross-over to other arm.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Cinnamon</intervention_name>
    <description>Cinnamon supplement</description>
    <arm_group_label>Cinnamon</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy human adults age &gt;=20 years' old&#xD;
&#xD;
          -  Typically consume low fiber/polyphenol diet (beige diet see below)&#xD;
&#xD;
          -  Overweight/obese individuals with a BMI of 25 to 40 kg/m2 and HbA1c &gt;=5.6% and &lt;=&#xD;
             6.5%.&#xD;
&#xD;
          -  Subjects must read and sign the Institutional Review Board-approved written informed&#xD;
             consent prior to the initiation of any study specific procedures or enrollment. A&#xD;
             subject will be excluded for any condition that might compromise the ability to give&#xD;
             truly informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any subjects with cinnamon intolerance&#xD;
&#xD;
          -  Any subject with a screening laboratory value outside of the laboratory normal range&#xD;
             that is considered clinically significant for study participation by the investigator.&#xD;
&#xD;
          -  Any subject currently taking blood thinning medications such as Warfarin or Coumadin&#xD;
&#xD;
          -  Any history of gastrointestinal disease or surgery except for appendectomy or&#xD;
             cholecystectomy.&#xD;
&#xD;
          -  Eating a high fiber/polyphenol diet or taking any medication or dietary supplement,&#xD;
             which interfere with the absorption of polyphenols.&#xD;
&#xD;
          -  History of gastrointestinal surgery, diabetes mellitus on medications, or other&#xD;
             serious medical condition, such as chronic hepatic or renal disease, bleeding&#xD;
             disorder, congestive heart disease, chronic diarrhea disorders, myocardial infarction,&#xD;
             coronary artery bypass graft, angioplasty within 6 months prior to screening, current&#xD;
             diagnosis of uncontrolled hypertension (defined as systolic BP &gt;160mmHg, diastolic BP&#xD;
             &gt;95mmHg), active or chronic gastrointestinal disorders, bulimia, anorexia, laxative&#xD;
             abuse, or endocrine diseases (except thyroid disease requiring medication) as&#xD;
             indicated by medical history.&#xD;
&#xD;
          -  Pregnant or breastfeeding&#xD;
&#xD;
          -  Currently uses tobacco products.&#xD;
&#xD;
          -  Currently has an alcohol intake &gt;= 20 g ⁄ day;&#xD;
&#xD;
          -  Currently has a coffee intake &gt;= 3 cups ⁄ day;&#xD;
&#xD;
          -  Allergy or sensitivity to cinnamon. Subjects will be excluded if there is a prior&#xD;
             history of such sensitivity. Since these foods are commonly eaten and allergies are&#xD;
             rare, subjects should be aware of this sensitivity prior to entering the study. To&#xD;
             determine this, a positive history of cinnamon ingestion without incident will be&#xD;
             requested. In addition, any subject with a history of allergy or anaphylaxis of any&#xD;
             kind will be excluded&#xD;
&#xD;
          -  Is unable or unwilling to comply with the study protocol.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zhaoping Li</last_name>
    <role>Principal Investigator</role>
    <affiliation>UCLA Professor of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gail Thames</last_name>
    <phone>310-825-0453</phone>
    <email>gthames@mednet.ucla.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Dina Ben-Nissan</last_name>
    <phone>310-206-2582</phone>
    <email>Dbennissan@mednet.ucla.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>UCLA</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gail Thames</last_name>
      <phone>310-825-0453</phone>
      <email>gthames@mednet.ucla.edu</email>
    </contact>
    <contact_backup>
      <last_name>Dina Ben-Nissan</last_name>
      <phone>310-206-2582</phone>
      <email>dbennissan@mednet.ucla.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Zhaoping Li</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 7, 2020</study_first_submitted>
  <study_first_submitted_qc>April 9, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 13, 2020</study_first_posted>
  <last_update_submitted>April 14, 2021</last_update_submitted>
  <last_update_submitted_qc>April 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, Los Angeles</investigator_affiliation>
    <investigator_full_name>Zhaoping Li</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>glucose</keyword>
  <keyword>cinnamon</keyword>
  <keyword>pre-diabetes</keyword>
  <keyword>microbiome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prediabetic State</mesh_term>
    <mesh_term>Glucose Intolerance</mesh_term>
    <mesh_term>Hyperglycemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

